跳至主要内容
临床试验/IRCT201607132017N30
IRCT201607132017N30已完成未知

Assessment of oleoylethanolamide supplementattion on the peroxisome proliferator-activated receptor-a (PPAR-a) gene expression, some inflammatory biomarkers, total antioxidant capacity, lipid profiles, fasting blood glucose, food intake and the abundence of Akkermansia muciniphila bacteria in stool of obese people: A double-blind randomized placebo-controlled clinical trial

Vice-Chancellor for Research of Tabriz University of Medical Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 50 years(—)
性别
All

入选标准

  • healthy obese subjects in both genders (males and females)
  • Ages between 18 to 59 years
  • body mass index 30-40 kg/m2

排除标准

  • having kidney problems, liver failure, heart failure, rheumatic diseases and gastrointestinal diseases
  • Breastfeeding and pregnancy and menopause
  • Taking probiotic and prebiotic supplements, vitamin, minerals, omega-3 and weight-reducing drugs and antibiotics during past one month

研究者

发起方
Vice-Chancellor for Research of Tabriz University of Medical Sciences

相似试验